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Available online 28 December 2015Introduction:Nasalmucus and its proteins are a defence against allergens.We sought to investigate dynamic pro-
teome changes in allergic rhinitis upon environmental allergen provocation.
Methods: Nasal mucus was collected in and out of pollen season from allergic rhinitis patients (N = 10) and
healthy controls (N = 12). Liquid chromatography–tandem mass spectrometry was performed. Proteins were
identiﬁed by SwissProt database search and quantiﬁed from normalized areas under curve of precursor ion chro-
matograms. Gene enrichment analysis was performed with Cytoscape/BINGO software.
Results: In total 430 different proteins were detected in both groups, 203 (47.2%) were newly identiﬁed. In aller-
gics CLU and IGKC were signiﬁcantly more abundant in season (2.2 and 2.1-fold respectively). GSTP1 (0.5-fold),
ELANE (0.4-fold), HIST1H2BK (0.3-fold), S100A8 (0.2-fold), S100A12 (0.2-fold) and ARHGDIB (0.1-fold) were
signiﬁcantly less abundant in season. In healthy controls UBC, TUBA1B, HBB and FABP5were only present in sea-
son. Ig kappa chain V-I region DEE (5.3-fold), CLU (5.0-fold), TXN (4.3-fold), MSMB (3.2-fold) and Ig heavy chain
V-III region BRO (2.7-fold) were signiﬁcantly more abundant in season. MUC5B (0.5-fold), SLPI (0.2-fold) and
S100P (0.2-fold) were signiﬁcantly less abundant in season.
Conclusion: Contrary to their symptoms allergic rhinitis patients show perennial inﬂammatory response lacking
adequate reaction to allergens in season.
Biological signiﬁcance:Many studies dealing with allergic rhinitis are focused on the nasal epithelium. This is the
ﬁrst study to analyse the nasal mucus as primary defence barrier on a proteomic level in and out of pollen season
and contrary to the leading opinion shows that allergic patients show a perennial inﬂammatory response with
reduced reaction to allergens whereas healthy controls react on proteome basis towards enhanced defence in
season despite lacking allergic sensitization.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. IntroductionAllergic rhinitis is a global health problem affecting up to 40% of
the population in some regions regardless of gender or age [1]. The
pathophysiology of allergic rhinitis is well understood with affected
subjects being sensitized to otherwise harmless inhaled allergens.
Upon contact with the patients' immune system immune cells produce
IgE instead of IgGwhich causesmast cell degranulation and the classical
symptoms of nasal congestion and rhinorrhea [1,2]. Nevertheless the
process of sensitization is unclear. Environmental and many other fac-
tors have been proposed to explain why certain individuals develop al-
lergy and some not [3]. Nasal mucus is the ﬁrst line defence barrier
against allergens and its proteins might play a role in the sensitization
process and allergen interaction with the underlying epithelium [4,5].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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innate antiproteases and to prevent subsequent epithelial damage and
allergen transport through the mucosa [6–9]. Proteins exudated from
plasma could have immunomodulatory functions and inﬂuence disease
severity [10,11]. To understand the nasal mucus proteome proteomic
studies are feasible detecting a large range of proteins and facilitating
analysis of their origin and function [12].
We recently showed that there are signiﬁcant differences in nasal
mucus proteomebetween allergic rhinitis patients and healthy controls,
and that some proteins might be novel biomarkers and lead to better
understanding of the disease [13,14] Moreover, we validated our meth-
odology and conﬁrmed our mass spectrometry results by Western
Blotting of selected proteins [13,14]. In these previous studies patients
were analyzed at a single time point solely and thus seasonal differences
of the proteome could not be assessed. The present study is aimed at
resolving seasonal proteome changes in allergic rhinitis patients and
healthy controls to reveal whether pollen exposure leads to changes
of the nasal mucus proteome in dependence of disease. We therefore
collected nasal mucus of allergic rhinitis patients and healthy controls
at two distinct time points, i.e. in and out of pollen season. The obtained
paired dynamic proteome proﬁles were examined with respect to how
either group reacts to natural pollen exposure on a proteome level. Our
results further stratify and identify novel key proteins playing a role in
allergic rhinitis.
2. Material and methods
2.1. Patients
Sixty-eight individuals were enrolled in the study, with a drop out
number of 46, because they did not appear to the follow-up controls
or did not meet the inclusion criteria at the follow-up visit anymore,
like usage of topical and/or systemic corticosteroids, antihistamines or
any other immunomodulatory drugs. The remaining twenty-two
individuals (7 males, 15 females) with a mean age of 33 years (SD:
9.7 years) were included in the study group comprising 10 (45%) aller-
gic rhinitis patients and 12 (55%) healthy controls. Allergy status was
veriﬁed by skin prick tests (SPT, Allergopharma GmbH & Co. KG,
Reinbek, Germany) and speciﬁc IgE (ImmunoCAP, Thermo Fisher Scien-
tiﬁc Inc., Vienna, Austria) in all patients and controls. Patients sensitized
to house dust mite or animals solely were excluded to avoid bias due
to small sample size (Table 1 and supplementary Table E1). Thus, only
patients sensitized to pollen and also showing symptoms during
the pollen season were considered for evaluation. Patients with acute
and/or chronic sinusitis as deﬁned by the EPOS [15] guidelines were
also excluded, as were patients with malignant tumors and any infec-
tious or cardiopulmonary disease, or who had been treated withTable 1
Summarized epidemiologic data with distribution of gender, age, group as well as skin
prick test (SPT) for clinically relevant allergens, symptoms present and total IgE.
Parameter Allergic rhinitis Healthy controls
Number of patients 10 12
Demographics
Mean age, years (SD) 30.4 (8.4) 36.3 (10.1)
Women, % 75% 40%
Clinically relevant positive SPT
Alder/Hasel/Birchpollen 8 0
Grasspollenmix 9 0
Ragweedpollen 3 0
Symptoms during pollenseason
Allergic rhinitis 10 0
Allergic rhinitis and asthma 0 0
Total IgE (kU/l), (SEM) 136.1 (122.1) 42 (37.5)
SD: standard deviation.
SPT: skin prick test.
SEM: standard error of mean.systemic or topical drugs including antihistamines, corticosteroids, anti-
biotics, antifungals or any other immunomodulatory drugs in the four
weeks prior to the study. The same exclusion criteria applied to the con-
trols, whowere healthy volunteers recruited from the hospital staff. In-
formed consent was obtained from all participants (allergics and
controls) before enrolment. The studywas approved by the institutional
review board of the Medical University of Graz.
2.2. Sample collection
In pollen season (with clinical symptoms present in allergic rhinitis
patients) and out of pollen season (without clinical symptoms in allergic
rhinitis patients) nasal mucus was collected with a special suction
device (Sinus Secretion Collector, Medtronic Xomed Inc., Jacksonville,
Florida, USA). Healthy controls' samples were collected on the same
day as allergic rhinitis patients' samples. Without previous interven-
tions (decongestants, local anesthetics) untreated mucus was obtained
under endoscopic control from the nasal cavity andmiddlemeatuswith
meticulous care taken not to touch the mucosa. The mucus volume
obtained was equal in both groups. Then, mucus was deep-frozen at
−92 °C before processing for LC–MS/MS mass spectrometry.
For sample preparation and mass spectrometric analysis please see
methods supplement in the online repository. Proteomic experiments
were performed according to MIAPE (minimum information about a
proteomic experiment) [14,16].
2.3. Data analysis
The LC–MS/MS data were analyzed by searching the human
SwissProt public database (downloaded onMarch 10th 2012)with Pro-
teome Discoverer 1.4 (Thermo Scientiﬁc) and Mascot 2.2 (Matrix
Science, London, UK). Detailed settings: Enzyme: trypsin, max. missed
cleavage sites: 2, N-terminus: hydrogen, C-terminus: free acid, carba-
midomethylation on lysine as ﬁxed modiﬁcation, oxidized methionine
as variable modiﬁcation, maximum precursor charge 3; precursor
mass tolerance +/−0.05 Da, product mass tolerance +/−0.7 Da; ac-
ceptance parameters were 2 or more identiﬁed distinct peptides after
automatic validation (decoy search, FDR b 5%). Identiﬁed proteins
were annotated using data from Uniprot (www.uniprot.org). Areas
under the curve (AUCs) (i.e. mean areas of extracted ion chromato-
grams of the individual peptides matched to a protein) normalized on
the total AUC of all proteins in each sample were used to compare rela-
tive protein abundances of the same protein between groups [17]. Data
are reported as means and standard errors of mean (SEM). Statistical
analysis by Mann Whitney U test for seasonal or group differences and
multivariate analysis for seasonal and group differences were per-
formed with SPSS 18.0 software (Chicago, Illinois, USA). A p-value of
b0.05 was considered signiﬁcant.
Enrichment analysis was performed with BINGO 2.44 [18] in
Cytoscape 2.81 software (www.cytoscape.org) [18]. For statistical anal-
ysis of enrichment data created with BINGO/Cytoscape hypergeometric
tests were performed and corrected by Benjamini & Hochberg False
Discovery Rate (FDR) correction at a signiﬁcance level of 0.05.
3. Results
The mean total protein concentration over all samples was
0.58 mg/ml (SD: 0.66). Allergic rhinitis patients (AR) had a higher
mean protein concentration (0.78 mg/ml (SD: 0.87)) than healthy con-
trols (HC) (0.42 mg/ml (SD: 0.35)). However, this difference was not
signiﬁcant (p = 0.377). Overall 430 different proteins were detected
in both groups, while 327 were detected in AR and 366 in HC respec-
tively. Of these 203 proteins (47.2%) were newly identiﬁed as nasal
mucus proteins (supplementary Table E2). Themost abundant proteins
were Serumalbumin (ALB), LysozymeC (LYZ), Ig alpha-1 chain C region
(IGHA1) and Ig alpha-2 chain C region (IGHA2) independent of disease
Fig. 1. Differences in mean normalized areas under the curve between allergic rhinitis
patients (AR) and healthy controls (HC) IN and OUT of season for the 30 most abundant
proteins.
Fig. 2. Venn diagram of protein distribution (number of proteins) between groups and
seasons. A: allergics, H: healthy controls.
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ric abundance change with respect to group and seasonal differences
(Fig. 1).
In AR patients 280 proteins were detected in season and 259 out of
season. Of these 211 proteins were identiﬁed in and out of pollen sea-
son, 69 solely in season (with 36 exclusively identiﬁed in AR) and 48
solely out of season (with 18 exclusively in AR). In HC 328 proteins
were detected in season, and 242 out of season. Of these 204 proteins
were found in and out of season, 124 solely in season (with 65 exclu-
sively in HC) and 38 solely out of season (with 22 exclusively in HC).
The difference in abundance between the groups for proteins present
only either in or out of season was highly signiﬁcant (p = 0.004)
(Fig. 2).
3.1. Seasonal differences in allergic rhinitis patients
In AR patients eight proteins showed signiﬁcantly different
abundances in season as compared to out of pollen season. These
were Clusterin (CLU), Ig kappa chain C region (IGKC), Glutathione
S-transferase P (GSTP1), Neutrophil elastase (ELANE), Histone H2B
type 1-K (HIST1H2BK), Protein S100-A8 (S100A8), Protein S100-A12
(S100A12) and Rho GDP-dissociation inhibitor 2 (ARHGDIB). Of these
CLU and IGKC were signiﬁcantly more abundant in season (2.2 and2.1-fold respectively). GSTP1 (0.5-fold), ELANE (0.4-fold), HIST1H2BK
(0.3-fold), S100A8 (0.2-fold), S100A12 (0.2-fold) and ARHGDIB
(0.1-fold) were signiﬁcantly less abundant in season (Table 2).
3.2. Seasonal differences in healthy controls
In HC 12 proteins showed signiﬁcantly different abundances be-
tween the seasons. These were Polyubiquitin-C (UBC), Tubulin alpha-
1B (TUBA1B), Hemoglobin beta (HBB), fatty acid-binding protein, epi-
dermal (FABP5), Ig kappa chain V-I region DEE (N/A), Clusterin (CLU),
Thioredoxin (TXN), Beta-microseminoprotein (MSMB), Ig heavy chain
V-III region BRO, Mucin-5B (MUC5B), Antileukoproteinase (SLPI) and
Protein S100-P (S100P). Of these UBC, TUBA1B, HBB and FABP5 were
only present in pollen season. Ig kappa chain V-I region DEE (5.3-
fold), CLU (5.0-fold), TXN (4.3-fold), MSMB (3.2-fold) and Ig heavy
chain V-III region BRO (2.7-fold) were signiﬁcantly more abundant
in season as compared to out of pollen season. MUC5B (0.5-fold),
SLPI (0.2-fold) and S100P (0.2-fold) were signiﬁcantly less abundant
in season (Table 2).
3.3. In season differences between allergic rhinitis patients and healthy
controls
In pollen season 10 proteins were signiﬁcantly more abundant in
allergic rhinitis patients than in healthy controls. These were Comple-
ment C4-B (C4B), Alpha-1-acid glycoprotein 2 (ORM2), and Phospho-
lipid transfer protein (PLTP), which were not detected in HC at all; as
well as Alpha-2-macroglobulin (A2M, 13.2-fold), Apolipoprotein A-II
(APOA2, 9.4-fold), Vitamin D-binding protein (GC, 4.6-fold), Comple-
ment C3 (C3, 3.6-fold), Apolipoprotein A-I (APOA1, 3.6-fold), BPI fold-
containing family B member 2 (BPIFB2, 2.9-fold) and Clusterin (CLU,
2.6-fold) (Table 3).
3.4. Seasonal differences in biological processes of allergic rhinitis patients'
and healthy controls' proteome
In total 22 biological processes (BPs) were enriched in the
overall nasal mucus proteome of the whole study group compared to
the total human proteome. In allergic rhinitis patients nine BPs were
up-regulated in season while 14 were up-regulated out of season
(Fig. 3ab, supplementary Table E3). In healthy controls 21 BPs were
up-regulated in season and 4 up-regulated out of pollen season respec-
tively (Fig. 4ab, supplementary Table E3). The following BPswere exclu-
sively found in healthy controls: anatomical structure morphogenesis,
transport, cell differentiation, death as well as cell death. Vice versa,
the only BP not found in HC regardless of season of the processes
found to be enriched in allergic rhinitis patients was behavior.
Table 2
Signiﬁcant proteins for seasonal differences in allergic rhinitis patients andhealthy controlswithmean normalized areas under the curve (AUC [%]), SEM=standard error ofmean. Ratio of
mean (AUC [%]) of IN vs. OUT of season differences is presented. P. in “N”means presence of protein in number of patients/total number of probands, Acc. no. means accession number
obtained from SwissProt database. A p-value of b0.05 was considered signiﬁcant and was obtained by MannWhitney U-Test.
Timepoint
IN season OUT season Total
Group Acc. no. NCBI gene names
(primary )
p-Value Mean AUC
[%]
SEM AUC
[%]
P. in
“N”
Mean AUC
[%]
SEM AUC
[%]
P. in
“N”
Ratio IN vs.
OUT season
Mean AUC
[%]
SEM AUC
[%]
P. in
“N”
Allergic P10909 CLU 0.027 0.22 0.03 10/10 0.10 0.04 5/10 2.2 0.16 0.03 15/20
P01834 IGKC 0.008 4.36 0.76 10/10 2.11 0.29 10/10 2.1 3.24 0.47 20/20
P09211 GSTP1 0.037 0.17 0.07 5/10 0.37 0.06 1/10 0.5 0.27 0.05 15/20
P08246 ELANE 0.039 0.07 0.04 3/10 0.19 0.04 8/10 0.4 0.13 0.03 11/20
O60814 HIST1H2BK 0.029 0.21 0.08 6/10 0.65 0.21 1/10 0.3 0.43 0.12 16/20
P05109 S100A8 0.047 0.09 0.03 5/10 0.38 0.17 9/10 0.2 0.24 0.09 14/20
P80511 S100A12 0.045 0.04 0.03 2/10 0.19 0.06 7/10 0.2 0.12 0.04 9/20
P52566 ARHGDIB 0.034 0.02 0.02 1/10 0.15 0.04 6/10 0.1 0.09 0.03 7/20
Healthy P0CG48 UBC 0.014 0.11 0.05 6/12 0.00 0.00 0/12 N/A 0.05 0.03 6/24
P68363 TUBA1B 0.014 0.18 0.09 6/12 0.00 0.00 0/12 N/A 0.09 0.05 6/24
P68871 HBB 0.037 0.13 0.05 5/12 0.00 0.00 0/12 N/A 0.06 0.03 5/24
Q01469 FABP5 0.005 0.07 0.02 7/12 0.00 0.00 0/12 N/A 0.03 0.01 7/24
P01597 N/A 0.021 0.44 0.13 7/12 0.08 0.06 2/12 5.3 0.26 0.08 9/24
P10909 CLU 0.029 0.08 0.02 8/12 0.02 0.01 2/12 5.0 0.05 0.01 10/24
P10599 TXN 0.006 0.14 0.04 10/12 0.03 0.02 3/12 4.3 0.09 0.02 13/24
P08118 MSMB 0.027 0.16 0.05 7/12 0.05 0.05 1/12 3.2 0.10 0.03 8/24
P01766 N/A 0.000 0.59 0.08 12/12 0.22 0.06 8/12 2.7 0.40 0.06 20/24
Q9HC84 MUC5B 0.042 0.45 0.07 11/12 0.98 0.18 12/12 0.5 0.72 0.11 23/24
P03973 SLPI 0.005 0.58 0.15 10/12 2.44 0.57 11/12 0.2 1.51 0.35 21/24
P25815 S100P 0.008 0.02 0.02 1/12 0.10 0.03 8/12 0.2 0.06 0.02 9/24
Acc. no. = accession number obtained from UniProt database.
SEM= standard error of mean.
AUC = mean normalized area under the curve.
P. in “N” A or H = presence of protein in number of patients/total number of probands.
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Nasal mucus is the ﬁrst line defence barrier of the nasal mucosa
against various inhaled noxa like allergens. Its proteins harbor speciﬁc
functions that could play a role in the pathophysiology of allergic rhini-
tis.We recently demonstrated that, on a proteome level, nasal mucus of
allergic rhinitis patients and healthy controls showed signiﬁcant differ-
ences [14]. These mainly addressed immune response, mucus and mu-
cosal homeostasis inﬂuencing epithelial permeability, and protease/
antiprotease balance. Furthermore potential new biomarkers such as
apolipoproteins were identiﬁed to be enriched in allergic rhinitis that
could play an immunomodulatory role apart from their function in
lipid metabolism [13,19–23].
In this study we performed a seasonal analysis of the nasal
mucus proteome in allergic rhinitis to obtain information about itsTable 3
Signiﬁcantly different proteins in season between allergic rhinitis patients and healthy control
Ratio of mean (AUC[%]) of IN vs. OUT of season differences is presented. P. in “N”means prese
number obtained from SwissProt database. A p-value of b0.05 was considered signiﬁcant and
Acc. no. NCBI gene names
(primary)
p-Value Mean AUC
[%] allergic
SEM AUC
[%]
P55058 PLTP 0.029 0.1 .1
P19652 ORM2 0.010 0.1 .0
P0C0L5 C4B 0.010 0.1 .0
P01023 A2M 0.002 0.2 .1
P02652 APOA2 0.001 0.5 .2
P02774 GC 0.034 0.2 .1
P01024 C3 0.043 0.3 .1
P02647 APOA1 0.011 1.5 .5
Q8N4F0 BPIFB2 0.017 0.4 .1
P10909 CLU 0.002 0.2 .0
A: allergic rhinitis patients, H: healthy controls.
Acc. no.: accession number obtained from UniProt database.
AUC: mean normalized area under the curve.
SEM: standard error of mean.
P. in “N” A or H: presence of protein in number of patients/total number of probands.changes caused by natural pollen exposure. Therefore, mucus from all
participants was obtained at two time points, in and out of pollen sea-
son. Pollen exposure dependent nasal mucus proteome changes were
assessed both in allergic rhinitis patients and healthy controls. Among
themost abundant proteins in nasalmucus changeswere unremarkable
between the two groups as well as between in and out of pollen season
and showed a high overlapwith our previous results (Figs. 1 and 2) [14].
Interestingly the nasal mucus of allergic rhinitis patients contained sig-
niﬁcantly fewer proteins exclusively in season compared to healthy
controls (68 vs. 124) resembling a higher diversity of proteins in healthy
controls as a reaction to pollen exposure. The numerical change of dif-
ferent proteins exclusively present in as compared to out of season
wasmarkedly higher in healthy controls (124 vs. 38) compared to aller-
gic rhinitis patients (68 vs. 48). These data suggest a higher plasticity of
the healthy compared to the allergic mucus proteome.s with mean normalized areas under the curve (AUC [%]), SEM= standard error of mean.
nce of protein in number of patients/total number of probands, Acc. no. means accession
was obtained by Mann Whitney U-Test.
P. in “N” Mean AUC
[%] healthy
Sem AUC
[%]
P. in “N” Ratio A vs.
H IN season
4/10 0.0 0.0 0/12 N/A
5/10 0.0 0.0 0/12 N/A
5/10 0.0 0.0 0/12 N/A
7/10 0.0 .0 2/12 13.2
9/10 0.1 .0 3/12 9.4
7/10 0.1 .0 6/12 4.6
7/10 0.1 .0 6/12 3.6
10/10 0.4 .2 10/12 3.6
10/10 0.1 .0 8/12 2.9
10/10 0.1 .0 8/12 2.6
Fig. 3. Enrichment analysis of biological processes, obtained by BINGO software. Signiﬁcantly enriched biological processes of proteins present in allergic rhinitis patients (N = 17)
compared to total human proteome, 9 of these up-regulated in season a) and 14 up-regulated out of season b). Red nodes indicate silenced biological processes. Colour bar in the right
lower quadrant indicates level of signiﬁcance from low (yellow) to high (orange). Statistical analysis was performed with a hypergeometrical test. A p-value of b0.05 was considered
signiﬁcant.
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from the plasma. Five percent are produced by the epithelium and gob-
let cells and around 11% originate from immune cells (see tissue speci-
ﬁcity in Table E3). The vast majority of proteins has not been described
so far or been allocated to the nasalmucus underlying the diversity of its
proteome and potential impact on disease. Correlation of nasal mucus
protein expression to epithelial protein expression and plasma proteinlevels in the future will further facilitate elucidation of the protein
origins.
Only Clusterin (CLU) and Ig kappa chain C region (IGKC) were signif-
icantly more abundant in allergic rhinitis patients in as compared to out
of season;while six proteinswere signiﬁcantlymore abundant out of sea-
son: Glutathione S-transferase P (GSTP1), Neutrophil elastase (ELANE),
Histone H2B type 1-K (HIST1H2BK), Protein S100-A8 (S100A8), Protein
Fig. 4. Enrichment analysis of biological processes, obtained by BINGO software, of signiﬁcantly enriched biological processes of proteins present in healthy controls (N=21) compared to
total human proteome, 21 of these up-regulated in season a) and 4 up-regulated out of season b). Red nodes indicate silenced biological processes. Colour bar in the right lower quadrant
indicates level of signiﬁcance from low (yellow) to high (orange). Statistical analysis was performed with a hypergeometrical test. A p-value of b0.05 was considered signiﬁcant.
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GSTP1 negatively regulates acute inﬂammatory response and apoptosis
[24]. ELANE, S100A8 and S100A12 contrarily have proinﬂammatory
functions promoting neutrophil chemotaxis, chemokine and cytokine
production. ELANE furthermore destroys bacteria through its serine
protease activity [25–27]. Elevated usually intracellularly found
proteins, like histone protein HIST1H2BK and Rho protein regulator
ARHGDIBmay be a result of tissue damage and/or repair. ARHGDIB neg-
atively regulates cell adhesion and cytoskeleton organization, which
can inﬂuence the immune response [28,29]. On the other hand, thecytoskeleton protein TUBA1B was found in season exclusively in
healthy controls. It is a major constituent of microtubules whose func-
tions are cell organelle positioning, intracellular trafﬁcking, cell polari-
zation and anchoring tight junction proteins giving epithelial cells an
apico-basal orientation for enhanced epithelial integrity. In this respect
Statherin is another interesting protein showing the most striking dia-
metric abundance changes with respect to seasonal as well as inter-
groupdifferences (Fig. 1). It ismost abundant in allergic rhinitis patients
out of season and in healthy controls in season. It strengthens epithelial
integrity through cell organization, motility, polarity and anchoring
159P.V. Tomazic et al. / Journal of Proteomics 133 (2016) 153–160tight junctions promoting cell adhesion and thus stabilizes the nasal
mucus [30]. This underlines that on a proteome level nasal mucus of al-
lergic rhinitis patients shows an impaired defence during pollen season
and that remodeling as well as inﬂammatory responses are prolonged
outside pollen season, contrarily healthy controls show immune re-
sponse and enhanced defence capacity of the nasal mucus and subse-
quently the epithelium in season as a consequence to pollen exposure.
Next to TUBA1B healthy controls had 8 other signiﬁcantly more
abundant proteins in their nasal mucus in season compared to out of
season: Polyubiquitin-C (UBC), Hemoglobin beta (HBB), FA-binding
protein epidermal (FABP5), Ig kappa chain V-I region DEE and Ig
heavy chain V-III region BRO, Clusterin (CLU), Thioredoxin (TXN), and
Beta-microseminoprotein (MSMB) with the ﬁrst three and TUBA1B ex-
clusively present in season. UBC when covalently bound to target pro-
teins leads to degradation of the latter via the proteasome suggesting
a high degree of protein turnover in healthy controls in season [31,32].
Secreted CLU protects from apoptosis and cytolysis by complement in-
hibition and promotes cell interaction, membrane protection and tissue
repair [33–35]. CLUwas also found to be signiﬁcantly more abundant in
season in allergic rhinitis patients suggesting that the CLU dependent
tissue protection mechanism is intact in allergic rhinitis. FABP5 is a
member of the fatty acid binding protein family which is involved in
fatty acid transport andmetabolism. It is important for the development
of keratinocytes and epidermal appendices like sebaceous glands.
FABP5 is responsible for the integrity of the cutaneous barrier, but
could also share the same function for the mucosal barrier [36]. Despite
mucus was meticulously obtained from the middle meatus it is more
likely that FABP5 originates from the nasal vestibule and migrated into
the nasal cavity by mucociliary transport.
TXN regulates reactive oxidative metabolism playing an important
role in scavenging reactive oxygen species. It was shown to suppress in-
ﬂammation in an animal asthma model and eosinophil recruitment as
well as goblet cell hyperplasia [37–40]. MSMB is known for its presence
in prostate and involvement in prostate cancer [41], but was recently
shown to be down-regulated in respiratory syncytial virus infection of
the nasopharynx [42] and in asthmatic patients [43]. Thus TXN and
MSMB may have protective effects for the epithelium in healthy con-
trols during pollen season.
On the other hand, three proteins, namely Mucin-5B (MUC5B),
Antileukoproteinase (SLPI) and Protein S100-P (S100P) were signiﬁ-
cantlymore abundant out of season as compared to in season in healthy
controls. MUC5B is a major constituent of nasal mucus inﬂuencing its
viscosity. S100P is involved in the formation of microvilli thus responsi-
ble for a normal mucosal cell function and mucociliary clearance.
These proteins reﬂect a normal state of the mucus [5,44–46]. SLPI has
antiprotease activity for trypsin, chymotrypsin, elastase, and cathepsin
G. Its function is to prevent protease damage to the mucosa [47–51].
SLPI was also signiﬁcantly more abundant in healthy controls as com-
pared to allergic rhinitis patients in our previous study as well as other
antiproteases [13,14]. However, it has been published that proteases
frompollen are only sufﬁciently inhibited by cysteine antiproteases [52].
When comparing the nasal mucus proteome of allergic rhinitis pa-
tients and healthy controls in pollen season 10 proteins were found to
be signiﬁcantlymore abundant in allergic rhinitis. Of these Complement
C4-B (C4B), Alpha-1-acid glycoprotein 2 (ORM2) and Phospholipid
transfer protein (PLTP) were exclusively present in allergic rhinitis;
while Alpha-2-macroglobulin (A2M), Apolipoprotein A-II (APOA2), Vi-
tamin D-binding protein (GC), Complement C3 (C3), Apolipoprotein
A-I (APOA1), BPI fold-containing family Bmember 2 (BPIFB2), and Clus-
terin (CLU) were also found in healthy controls. Most of these proteins
are also found in plasma andmay indicate therefore increased plasma ex-
udation in allergic rhinitis [53,54] which may indicate disintegration of
the epithelial barrier in allergy [55–57]. C3, A2M, APOA1 and APOA2
were also found to be signiﬁcantly more abundant in nasal mucus in al-
lergic rhinitis patients in our previous studies [13,14]. Apolipoproteins
could act as anti-inﬂammatory agents apart from their involvement inlipid metabolism [19,20] and their high abundance could be regulated
by a local mechanism since plasma levels of APOs did not differ between
allergic rhinitis patients and healthy controls and did not correlate to
nasal mucus levels [13]. However, further studies are needed to investi-
gate the local production of APOs in the epithelium as a possible alterna-
tive mechanism to increased plasma exudation. On the other hand, APOs
could also act pro-inﬂammatory through posttranslational modiﬁcations
and complexation with other molecules in chronic inﬂammation [22].
PLTP is responsible for phospholipid transfer between lipoproteins and
is elevated in plasma during acute inﬂammation. Interestingly, it binds
to Apolipoprotein A-I, Apolipoprotein E and Clusterin and forms com-
plexes involved in immune response [58]. C3, C4B, ORM2 [59], BPIFB2
[60–62] and GC [63] are pro-inﬂammatory molecules acting over differ-
ent ways like the complement system or innate immune cells. As ORM2
was newly identiﬁed in the nasal mucus in the present study its role in
the upper airway tract needs to be elucidated.
On the basis of the nasal mucus proteome allergic rhinitis patients
– contrary to the absence of symptoms out of season – show peren-
nial inﬂammatory response increasing during pollen season despite
reduced defence mechanisms of the immune system and reduced in-
tegrity of the epithelial barrier. Moreover, fewer different proteins
are expressed in season reﬂecting a reduced plasticity of the allergic
proteomewhich can also be seen in the lower number of enriched bi-
ological processes. In season allergic rhinitis patients lack enrich-
ment of processes like cytoskeleton organization, cell proliferation
or cellular homeostasis in contrary to healthy controls. In healthy
controls all these important biological processes are enriched in sea-
son whereas out of season several of these processes are not found to
be enriched. On a genomic level similar ﬁndings were seen in prima-
ry epithelial cells cultured form healthy controls that were exposed
to house dust mite allergen. The mRNA expression proﬁle showed
an up-regulation of chemokines, growth factors and structural pro-
teins as well as transcription factors upon provocation whereas epi-
thelial cells from allergics were already in activated state at baseline
[64].5. Conclusion
Contrary to symptom expression allergic rhinitis patients show an
increased inﬂammatory response in their nasal mucus proteome even
out of pollen season. In combinationwith reduced defencemechanisms
and an increase in inﬂammation in season the nasal mucus proteome
reﬂects a decreased plasticity and thus inadequate reaction to allergen
stress contrary to healthy controls. Our results also suggest that healthy
controls express proteins in their mucus that protect them against
harmful pollen content and subsequent sensitization to allergens.
Some of our identiﬁed proteins could serve as novel biomarkers for
allergic rhinitis. Functional analysis of distinct signiﬁcantly altered pro-
teins will further increase our understanding of the pathophysiology
of nasal mucus as defence barrier, whichmay be the basis of novel ther-
apeutic strategies.
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